Literature DB >> 19084027

Behavioural and neurochemical response of alpha-synuclein A30P transgenic mice to the effects of L-DOPA.

Mari Oksman1, Heikki Tanila, Leonid Yavich.   

Abstract

Transgenic mice carrying human A30P mutated alpha-synuclein demonstrate hypolocomotion and dysfunction of the presynaptic machinery of dopamine overflow, induced by reducing capacity of the dopamine storage pool. We suggested that overexpression of alpha-synuclein may change sensitivity of these mice to L-DOPA. Current study assessed behavioural and neurochemical responses in A30P mice to L-DOPA using automated activity monitoring and voltammetry. We confirmed decreased locomotion and rearing of A30P transgenic mice compared to wild-type controls. L-DOPA (10-200mg/kg, i.p.) dose-dependently lowered locomotor activity, including stereotypy, in both genotypes, but the effects were larger in A30P mice. The effects of drug on stimulated dopamine overflow were investigated in the nucleus accumbens shell. L-DOPA at the dose of 30mg/kg did not change peak dopamine overflow induced by 10Hz stimulation of the medial forebrain bundle in either genotype, but increased it at the higher (20-50Hz) frequencies of stimulation. At the higher frequencies of stimulation, L-DOPA elevated dopamine overflow significantly more in A30P mice than in the control animals. These data show that A30P transgenic mice are more sensitive to the effects of L-DOPA at both behavioural and neurochemical level.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19084027     DOI: 10.1016/j.neuropharm.2008.11.004

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  8 in total

1.  Chronic administration of cholesterol oximes in mice increases transcription of cytoprotective genes and improves transcriptome alterations induced by alpha-synuclein overexpression in nigrostriatal dopaminergic neurons.

Authors:  Franziska Richter; Fuying Gao; Vera Medvedeva; Patrick Lee; Nicholas Bove; Sheila M Fleming; Magali Michaud; Vincent Lemesre; Stefano Patassini; Krystal De La Rosa; Caitlin K Mulligan; Pedrom C Sioshansi; Chunni Zhu; Giovanni Coppola; Thierry Bordet; Rebecca M Pruss; Marie-Françoise Chesselet
Journal:  Neurobiol Dis       Date:  2014-05-18       Impact factor: 5.996

Review 2.  Behavioral phenotyping of mouse models of Parkinson's disease.

Authors:  Tonya N Taylor; James G Greene; Gary W Miller
Journal:  Behav Brain Res       Date:  2010-03-06       Impact factor: 3.332

3.  BL-1023 improves behavior and neuronal survival in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-intoxicated mice.

Authors:  J A L Hutter-Saunders; L M Kosloski; J M McMillan; N Yotam; T Rinat; R L Mosley; H E Gendelman
Journal:  Neuroscience       Date:  2011-02-12       Impact factor: 3.590

Review 4.  A progressive mouse model of Parkinson's disease: the Thy1-aSyn ("Line 61") mice.

Authors:  Marie-Francoise Chesselet; Franziska Richter; Chunni Zhu; Iddo Magen; Melanie B Watson; Sudhakar R Subramaniam
Journal:  Neurotherapeutics       Date:  2012-04       Impact factor: 7.620

5.  Interleukin-22 protects rat PC12 pheochromocytoma cells from serum deprivation-induced cell death.

Authors:  Yongchun Liu; Wenyan Pan; Shengmei Yang; Xiaoying Wu; Jianfu Wu; Jun Ma; Zengqiang Yuan; Songshu Meng
Journal:  Mol Cell Biochem       Date:  2012-09-16       Impact factor: 3.396

Review 6.  Parkinson's disease mouse models in translational research.

Authors:  Paul M A Antony; Nico J Diederich; Rudi Balling
Journal:  Mamm Genome       Date:  2011-05-11       Impact factor: 2.957

7.  Walking deficits and centrophobism in an α-synuclein fly model of Parkinson's disease.

Authors:  A Y Chen; P Wilburn; X Hao; T Tully
Journal:  Genes Brain Behav       Date:  2014-10-14       Impact factor: 3.449

8.  Behavioral characterization of A53T mice reveals early and late stage deficits related to Parkinson's disease.

Authors:  Katrina L Paumier; Stacey J Sukoff Rizzo; Zdenek Berger; Yi Chen; Cathleen Gonzales; Edward Kaftan; Li Li; Susan Lotarski; Michael Monaghan; Wei Shen; Polina Stolyar; Dmytro Vasilyev; Margaret Zaleska; Warren D Hirst; John Dunlop
Journal:  PLoS One       Date:  2013-08-01       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.